The drug got a green light today, not the final green light, but it is good news.
from here
March 29 (Bloomberg) -- Dendreon Corp.'s prostate cancer drug Provenge was recommended for U.S. approval as the first treatment to stimulate the body's immune system against tumor cells.
How it Works
The drug, called an immunotherapy, doesn't work like a traditional cancer treatment. Blood is drawn from a patient, and some white blood cells vital to the immune system are separated in a lab.
The white blood cells are shipped to the company and incubated with a genetically engineered protein found on prostate cancer cells. The white blood cells are supposed to recognize the protein as an invader and attack the cells that contain it. The revved-up white blood cells are then shipped back and re-infused into the patient.
No comments:
Post a Comment